Astrana Health (NASDAQ:ASTH) Shares Up 3.9% – Here’s Why

Astrana Health, Inc. (NASDAQ:ASTH)’s stock price rose 3.9% during mid-day trading on Tuesday . The stock traded as high as $31.66 and last traded at $31.81. Approximately 130,682 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 249,187 shares. The stock had previously closed at $30.60.

Analyst Upgrades and Downgrades

ASTH has been the topic of several research reports. Truist Financial dropped their price target on Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a research report on Tuesday. Stifel Nicolaus reduced their target price on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Bank of America decreased their price target on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Macquarie upgraded shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. Finally, Robert W. Baird lowered their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $56.17.

Astrana Health Price Performance

The firm has a 50-day moving average of $33.96 and a 200-day moving average of $42.76. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The firm has a market capitalization of $1.73 billion, a P/E ratio of 23.71, a PEG ratio of 1.37 and a beta of 1.30.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The company had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. As a group, analysts predict that Astrana Health, Inc. will post 1.15 EPS for the current year.

Institutional Trading of Astrana Health

Hedge funds have recently bought and sold shares of the company. Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Astrana Health during the 4th quarter valued at about $40,000. Quarry LP lifted its stake in shares of Astrana Health by 35.5% during the 4th quarter. Quarry LP now owns 1,799 shares of the company’s stock valued at $57,000 after buying an additional 471 shares in the last quarter. KBC Group NV purchased a new position in shares of Astrana Health in the third quarter valued at about $70,000. Quest Partners LLC bought a new position in Astrana Health in the 3rd quarter worth approximately $133,000. Finally, US Bancorp DE lifted its holdings in shares of Astrana Health by 3,880.0% in the fourth quarter. US Bancorp DE now owns 4,776 shares of the company’s stock worth $151,000 after buying an additional 4,656 shares in the last quarter. Hedge funds and other institutional investors own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.